Topotecan and Melphalan for Retinoblastoma

• Status: Recruiting
• Trial end date: 2027-12-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Melphalan; Topotecan

Criteria

Inclusion Criteria:

• diagnosed as retinoblastoma

• receiving eyeball-sparing treatment

Exclusion Criteria:

• disease progression during follow-up